Probiotics and prebiotics

Probiotics are live microorganisms that confer a health benefit when administered in adequate amounts, but that definition is strain-specific: Lactobacillus rhamnosus GG and Bifidobacterium infantis 35624 are not interchangeable products even if both appear as “Lactobacillus/Bifidobacterium” on a report. Prebiotics are substrates selectively utilized by host microorganisms (classically inulin, fructo-oligosaccharides, galacto-oligosaccharides); they increase fermentation in the colon, which helps some endpoints and worsens bloating in others when FODMAP load is high.

Consumer reports that flag low Bifidobacterium or “dysbiosis” rarely tell you which strain trial applies to your symptoms, or whether a prebiotic will increase gas production before it increases the taxon you care about.

Definitions (ISAPP consensus framing)

Term	Meaning
Probiotic	Live microbe conferring health benefit at adequate dose, strain-specific (Hill et al., 2014)
Prebiotic	Substrate selectively utilized by host microbes with demonstrated health benefit, fibre structure matters
Synbiotic	Combined product; evidence varies by formulation, not by category label
Postbiotic	Inactivated microbes or their components, emerging category; same strain specificity applies

Evidence tiers (simplified)

Intervention	Stronger evidence context	Weaker / mixed
Named probiotic strains	Selected strains in antibiotic-associated diarrhoea, pouchitis, some IBS endpoints (network meta-analyses show strain heterogeneity)	Generic “gut health” blends without indication-matched trials
Inulin / FOS / GOS	Increases Bifidobacterium in many human feeding studies	IBS symptom flare; overlaps low-FODMAP exclusion
Resistant starch	Supports butyrate producers in some cohorts	Individual non-response; gas if titrated too fast
Psyllium (soluble fibre)	IBS and constipation symptom bundles in meta-analyses	Not a classic prebiotic definition but often first-line fibre

AGA guidance is conditional on strain-specific products for several indications, not a blanket endorsement of all commercial probiotics. ACG IBS guidance similarly avoids recommending generic probiotics for all patients.

Intervention pages: Lactobacillus/Bifidobacterium blend, Low-FODMAP diet.

What not to conclude from a microbiome report

Report line	Common over-read	More accurate framing
Low Bifidobacterium	“I need any probiotic with Bifido”	Genus bin ≠ administered strain; some strains lack constipation evidence
↑ Bifidobacterium after product X in a trial	“My panel will match if I buy it”	Trial dose, duration, and sequencing method differ from consumer panels
No taxonomic change after 4 weeks	“Probiotic failed”	Clinical endpoints (stool frequency, pain) can shift without genus-level detection
Dysbiosis flag	“Synbiotic stack required”	No validated algorithm maps dysbiosis scores to product lists

Colonization is often transient. PCR-based sequencing may detect DNA from dead cells depending on extraction and pipeline, a rise in reads is not proof of engraftment.

Prebiotics vs FODMAP restriction, timing conflict

Low-FODMAP diets reduce many fermentable oligosaccharides that double as prebiotics. Trials show Bifidobacteria can fall during strict low-FODMAP phases (Staudacher et al., 2017). Reintroduction or targeted prebiotic fibres after symptom stabilization is the usual clinical sequence, not permanent prebiotic loading while actively bloated.

Cross-links: FODMAPs, Dietary fiber, SCFAs, Chronic bloating, Constipation.